Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angioimmunoblastic T-cell lymphoma mice model.
Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S. Sato F, et al. Among authors: mori f. Leuk Res. 2013 Jan;37(1):21-7. doi: 10.1016/j.leukres.2012.09.009. Epub 2012 Sep 29. Leuk Res. 2013. PMID: 23026775
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.
Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, Ishida T, Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, Ueda R, Iida S. Inagaki A, et al. Among authors: mori f. Leuk Res. 2013 Dec;37(12):1648-55. doi: 10.1016/j.leukres.2013.09.026. Epub 2013 Oct 18. Leuk Res. 2013. PMID: 24210217
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Inagaki H, Suzuki A, Ueda R. Yano H, et al. Among authors: mori f. Cancer Sci. 2008 Nov;99(11):2309-14. doi: 10.1111/j.1349-7006.2008.00936.x. Epub 2008 Sep 1. Cancer Sci. 2008. PMID: 18771527 Free PMC article.
Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Ito A, et al. Among authors: mori f. Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2. Cancer Immunol Immunother. 2009. PMID: 19048251 Free PMC article.
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity.
Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A, Ishida T, Nitta M, Ueda R. Ding J, et al. Among authors: mori f. Blood. 2009 Oct 8;114(15):3325-8. doi: 10.1182/blood-2008-04-149047. Epub 2009 May 29. Blood. 2009. PMID: 19483125 Free article.
Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Ito A, et al. Among authors: mori f. J Immunol. 2009 Oct 1;183(7):4782-91. doi: 10.4049/jimmunol.0900699. Epub 2009 Sep 11. J Immunol. 2009. PMID: 19748990 Clinical Trial.
1,188 results